Aurora Oncology

Executive Summary

Aurora Oncology is a private San Diego-based biotech founded in 2018, focused on developing EGFR-targeted therapies and diagnostics for bladder cancer. Leveraging foundational research from the University of Colorado Cancer Center, the company aims to address the significant unmet need in bladder cancer, particularly for early-stage and non-invasive detection. Its lead programs include a localized EGFR-targeted therapy designed to minimize systemic toxicity and a companion diagnostic for early disease detection. Given the high prevalence of EGFR overexpression in bladder cancer and the potential for improved patient outcomes, Aurora's platform could offer a differentiated approach in a competitive landscape. The company is currently in preclinical/early clinical stages and is actively seeking partnerships to advance its pipeline.

Upcoming Catalysts (preview)

• H2 2026Initiation of First-in-Human Phase 1 Trial for EGFR-Targeted Therapy30% success
• Q2 2026Presentation of Preclinical Data at Major Oncology Conference80% success
• H1 2027Announcement of Strategic Partnership or Licensing Deal40% success